FOXG1 Antisense Oligonucleotides for Premature Neuronal Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological diseases and neurodevelopmental disorders, such as FOXG1 syndrome, are inadequate in addressing the premature differentiation of neuronal progenitor cells and the resulting developmental abnormalities, including epilepsy, microcephaly, and intellectual disability.
Innovation Solution
The use of antisense oligonucleotides (ASOs) that are complementary to the FOXG1 gene, specifically designed to inhibit FOXG1 expression or activity, are administered to target and suppress the premature differentiation of neuronal progenitor cells, thereby promoting normal brain development.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for neurological diseases, then general symptom management is provided, but premature differentiation of neuronal progenitor cells and resulting developmental abnormalities are not addressed
Solution Approach 1:
The patent uses antisense oligonucleotides as intermediary molecules that specifically bind to FOXG1 mRNA to prevent its translation into protein. This mediator approach allows selective inhibition of the harmful FOXG1 protein while leaving other cellular processes intact, thereby addressing the specific disease mechanism without affecting general brain function.
Solution Approach 2:
The invention extracts and targets the specific pathological element (FOXG1 protein) responsible for the disease mechanism. By using ASOs that specifically bind to FOXG1 mRNA, the treatment removes or neutralizes only the harmful protein while preserving normal neuronal development processes, thus addressing the specific disease mechanism rather than providing general symptom management.
2Stability of the object's composition
If FOXG1 expression is not inhibited, then neuronal progenitor cells undergo premature differentiation, but normal brain development is disrupted
Solution Approach 1:
The patent applies preliminary action by administering ASOs before premature differentiation occurs. The ASOs bind to FOXG1 mRNA early in the developmental process, preventing the translation of FOXG1 protein that would trigger premature differentiation. This preliminary inhibition maintains the neuronal progenitor pool and allows normal brain development to proceed.
Solution Approach 2:
The ASO acts as an intermediary that specifically blocks the FOXG1 protein's ability to induce premature differentiation. By binding to FOXG1 mRNA, the ASO prevents the formation of the harmful protein while allowing other necessary developmental processes to occur, thus maintaining progenitor cell stability without disrupting normal development.
3Reliability
If antisense oligonucleotides are administered, then FOXG1 activity is suppressed and brain development improves, but treatment complexity increases
Solution Approach 1:
The patent modifies the chemical parameters of the oligonucleotide by incorporating phosphorothioate linkages and modified nucleosides. These parameter changes enhance the stability, nuclease resistance, and binding affinity of the ASO, allowing it to effectively suppress FOXG1 activity in vivo while maintaining a relatively simple single-molecule structure that can be administered systemically.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ASOs effectively suppress FOXG1 activity, leading to improved brain development and reduced symptoms of FOXG1 syndrome, including epilepsy and intellectual disability, by enhancing neuronal progenitor cell survival and differentiation.
Implementation Method 1
an antisense oligonucleotide comprising a sequence and/or structure as set forth in Table 1 and 2, wherein the sequence or structure is at least 8-22 nucleotide in length and sequences that are at least 98-99% identical thereto and which inhibit the activity of FOXG1 AS and/or bind to FOXG1 AS
Data Source
AI summary
Disclosed is a method of treating a subject who has a neurological disease. The neurological disease may be associated with altered FOXG1 expression. In one aspect, the method includes a step of administering an effective dose of a FOXG1-AS antisense or inhibitory nucleic acid to a subject in need thereof, thereby rescuing the defects associated with altered FOXG1 expression.